References
[1] Mackey M, Glisovic S, Pastore Y, Krajinovic M, Craig M. The timing of cyclic cytotoxic chemotherapy can worsen neutropenia and neutrophilia. Brit J Clin Pharmacol 2020; EPub Ahead of Print.
[2] Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol 2018; 29: 1437-1444.
[3] Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther 2018 23; 11:955-965
[4] Barbolosi D, Ciccolini J, Lacarelle B, Barlési F, André N. Computational oncology–mathematical modelling of drug regimens for precision medicine. Nat Rev Clin Oncol 2016; 13:242-54.
[5] Ferrer F, Fanciullino R, Milano G, Ciccolini J. Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations Clin Pharm Ther 2020; EPub Ahead of Print.
[6] Friberg LE, Karlsson MO. Mechanistic Models for Myelosuppression. Investigational New Drugs 2003; 21: 183–194.
[7] Meille C, Barbolosi D, Ciccolini J, Freyer G, Iliadis A. Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy. Clin Pharmacokinet 2016; 55:1015-25.
[8] Hénin E, Meille C, Barbolosi D, You B, Guitton J, Iliadis A, Freyer G. Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients. Breast Cancer Res Treat 2016; 156: 331-41.
[9] Craig M, Humphries AR, Mackey M. mathematical model of granulopoiesis incorporating the negative feedback dynamics and kinetics of G-CSF/neutrophil binding and internalisation. Bull Math Biol 2016; 78: 2304–2357.